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To the Editor, 
We read with interest the important contribution of Carey et al. to the debate concerning 
US lipodystrophy assessments.[1]  
They excluded the possibility of using ultrasonography (US) to assess facial atrophy: in 
particular, they did not find a correlation with more established measures such as dual-
energy X-ray absorptiometry (DEXA) and computed tomography (CT), or with subjective 
severity scores assessed by physical examination or patient reports. However, although the 
use of US in assessing lipodystrophy alterations has objective difficulties in terms of 
standardization, its accuracy in measuring changes in subcutaneous fat thickness (SFT) at 
brachial, crural and malar level has been demonstrated by Martinez et al.[2], Asensi et al.[3] 
and ourselves.[4] 
Carey et al. chose the outer canthus of the right eye and the upper margin defined by malar 
bone as their reference point for the US determination of malar SFT, and this deserves 
some comment because, in our opinion, the correct way to determine the size of Bichàt’s 
bulla and measure malar SFT is to use a nasogenian transversal scan from the malar bone to 
the skin (Fig. 1).  
The reasons for this choice also include the clinical presentation of sunken cheeks and, after 
a long debate and a number of practical attempts with our radiologists, we believe that our 
scan is more representative of facial atrophy than the longitudinal image taken by Carey et 
al.[1]  
Our reference point corresponds to the deepest point of Bichàt’s bulla, which we think is 
the correct echographic reference point for measuring facial lipoatrophy whereas, in our 
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experience, the topographical site used by Carey et al. is too peripheral to guarantee a 
realistic description of fat loss. 
In addition to this crucial technical point, some other considerations need to be made. 
We feel that the most important correlation in this kind of investigation is with the patient’s 
body mass index (BMI) because subcutaneous and visceral fat distribution is related to the 
BMI in the majority of cases, with  lipoatrophy when BMI < 27 kg/m2 and lipohypertrophy 
when  BMI > 27 kg/m2. [5,6]  It is also well known that the presentation of lipodystrophy is 
often different in male and female HIV patients[7], and there is still controversy concerning 
gender-related differences in body fat distribution.[8] 
Comparing US and DEXA facial data is not necessarily appropriate because, by definition,  
DEXA cannot give any information about regional fat distribution and the simple DEXA 
evaluation of limb fat mass can be unreliable unless it is corrected by BMI.  
Similarly, attempts to correlate US determinations with CT scans of body regions other 
than the malar region carry the same risk of inaccuracy.  
The lack of correlation between patient and doctor judgments and US determinations can 
be easily explained on the basis of the choice of the topographic reference point discussed 
above.  
At the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 
(Paris, 2003), Milinkovic et al. [9] reported a good correlation between US and CT or 
DEXA subcutaneous fat measurements at similar levels.  
Although it has not yet been demonstrated that US can assess lipodystrophy, the possibility 
of at least partially replacing expensive methods of measuring fat alterations such as DEXA 
and CT is too important to be abandoned without further investigations. 
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Figure 1- US “malar skin point” for measuring facial lipoatrophy 
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